Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Even though pazopanib, a multitargeted tyrosine kinase inhibitor, has been approved for refractory soft tissue sarcoma (STS), little is known about the molecular determinants of the response to pazopanib. We performed integrative molecular characterization to identify potential predictors of pazopanib efficacy. Materials and Methods We obtained fresh pre-treatment tumor tissue from 35 patients with advanced STS receiving pazopanib-based treatment. Among those, 18 (51.4%) received pazopanib monotherapy, and the remaining 17 (48.6%) received pazopanib in combination with durvalumab, programmed death-ligand 1 blockade. Whole-exome and transcriptome sequencing were performed for each tumor and patient germline DNA. Results Of the 35 patients receiving pazopanib-based treatment, nine achieved a partial response (PR), resulting in an objective response rate (ORR) of 27.3%, and the median progression-free survival (PFS) was 6.0 months. Patients with CDK4 amplification (copy ratio tumor to normal > 2) exhibited shorter PFS (3.7 vs. 7.9 months, p=2.09×10–4) and a poorer response (ORR; 0% vs. 33.3%) compared to those without a gene amplification (copy ratio ≤ 2). Moreover, non-responders demonstrated transcriptional activation of CDK4 via DNA amplification, resulting in cell cycle activation. In the durvalumab combination cohort, seven of the 17 patients (41.2%) achieved a PR, and gene expression analysis revealed that durvalumab responders exhibited high immune/stromal cell infiltration, mainly comprising natural killer cells, compared to non-responders as well as increased expression of CD19, a B-cell marker. Conclusion Despite the limitation of heterogeneity in the study population and treatment, we identified possible molecular predictors of pazopanib efficacy that can be employed in future clinical trials aimed at evaluating therapeutic strategies.
Abstract
Purpose Even though pazopanib, a multitargeted tyrosine kinase inhibitor, has been approved for refractory soft tissue sarcoma (STS), little is known about the molecular determinants of the response to pazopanib. We performed integrative molecular characterization to identify potential predictors of pazopanib efficacy. Materials and Methods We obtained fresh pre-treatment tumor tissue from 35 patients with advanced STS receiving pazopanib-based treatment. Among those, 18 (51.4%) received pazopanib monotherapy, and the remaining 17 (48.6%) received pazopanib in combination with durvalumab, programmed death-ligand 1 blockade. Whole-exome and transcriptome sequencing were performed for each tumor and patient germline DNA. Results Of the 35 patients receiving pazopanib-based treatment, nine achieved a partial response (PR), resulting in an objective response rate (ORR) of 27.3%, and the median progression-free survival (PFS) was 6.0 months. Patients with CDK4 amplification (copy ratio tumor to normal > 2) exhibited shorter PFS (3.7 vs. 7.9 months, p=2.09×10–4) and a poorer response (ORR; 0% vs. 33.3%) compared to those without a gene amplification (copy ratio ≤ 2). Moreover, non-responders demonstrated transcriptional activation of CDK4 via DNA amplification, resulting in cell cycle activation. In the durvalumab combination cohort, seven of the 17 patients (41.2%) achieved a PR, and gene expression analysis revealed that durvalumab responders exhibited high immune/stromal cell infiltration, mainly comprising natural killer cells, compared to non-responders as well as increased expression of CD19, a B-cell marker. Conclusion Despite the limitation of heterogeneity in the study population and treatment, we identified possible molecular predictors of pazopanib efficacy that can be employed in future clinical trials aimed at evaluating therapeutic strategies.
참고문헌 (23)
- Hensley ML, "Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II trial", J Clin Oncol, 20, pp.2824~2831 (2002)
- Judson I, "Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma : a randomised controlled phase 3 trial", Lancet Oncol, 15, pp.415~423 (2014)
- Italiano A, "Trends in survival for patients with metastatic soft-tissue sarcoma", Cancer, 117, pp.1049~1054 (2011)
- Sleijfer S, "Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group(EORTC study 62043)", J Clin Oncol, 27, pp.3126~3132 (2009)
- van der Graaf WT, "Pazopanib for metastatic soft-tissue sarcoma(PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 379, pp.1879~1886 (2012)
- Tawbi HA, "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma(SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial", Lancet Oncol, 18, pp.1493~1501 (2017)
- Feng X, "Therapeutic implication of genomic landscape of adult metastatic sarcoma", JCO Precis Oncol, 3, pp.1~25 (2019)
- Baker SJ, "CDK4 : a key player in the cell cycle, development, and cancer", Genes Cancer, 3, pp.658~669 (2012)
- Becht E, "Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression", Genome Biol, 17, pp.218~ (2016)
- Sleijfer S, "Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma : an EORTC-STBSG study", Br J Cancer, 107, pp.639~645 (2012)
- Kobayashi H, "Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma", Int J Clin Oncol, 23, pp.368~374 (2018)
- Cancer Genome Atlas Research Network, "Comprehensive and integrated genomic characterization of adult soft tissue sarcomas", Cell, 171, pp.950~965 (2017)
- Barretina J, "Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy", Nat Genet, 42, pp.715~721 (2010)
- Nakamura T, "The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma : a Japanese Musculoskeletal Oncology Group(JMOG)study", Cancer, 122, pp.1408~1416 (2016)
- Semenza GL, "Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics", Oncogene, 29, pp.625~634 (2010)
- Zelzer E, "Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha", ARNT, 1998, pp.17, 5085~5094
- AACR Project GENIE Consortium, "AACR Project GENIE : powering precision medicine through an international consortium", Cancer Discov, 7, pp.818~831 (2017)
- Koehler K, "TP53 mutational status is predictive of pazopanib response in advanced sarcomas", Ann Oncol, 27, pp.539~543 (2016)
- Wheler JJ, "TP53 alterations correlate with response to VEGF", VEGFR inhibitors : implications for targeted therapeutics, 2016, pp.15, 2475~2485
- Petitprez F, "B cells are associated with survival and immunotherapy response in sarcoma", Nature, 577, pp.556~560 (2020)
- Allen E, "Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation", Sci Transl Med, 9, pp.eaak9679~ (2017)
- Aggen DH, "Targeting PD-1 or PD-L1 in metastatic kidney cancer : combination therapy in the first-line setting", Clin Cancer Res, 26, pp.2087~2095 (2020)
- Wilky BA, "Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma : a single-centre, single-arm, phase 2 trial", Lancet Oncol, 20, pp.837~848 (2019)